B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160

Benzinga Newsdesk www.benzinga.com Neutral 60.1%

Neg 0% Neu 60.1% Pos 0%

B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $160.